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Christopher J. Corrigan, PhD,a* and Hannah J. Gould, PhDa* London, United Kingdom, and Coimbra, PortugalBackground: Naturally occurring IgE-specific IgG autoantibodies
have been identified in patientswith asthmaand other diseases, but
their spectrum of functions is poorly understood.
Objective: Address the hypothesis that: (i) IgG anti-IgE
autoantibodies are detectable in the serum of all subjects but
elevated in asthmatic patients regardless of atopic status as
comparedwith controls; (ii) some activate IgE-sensitizedbasophils;
and (iii) some inhibit allergen-induced basophil activation.
Methods: IgE-specific IgG autoantibodies were detected and
quantified in sera using ELISA. Sera were examined for their
ability to activate IgE-sensitized human blood basophils in the
presence and absence of allergen using a basophil activation
test, and to inhibit allergen binding to specific IgE on a rat
basophilic cell line stably expressing human FcεRI.
Results: IgG autoantibodies binding to both free andFcεRI-bound
IgEweredetected inpatientswithatopic andnon-atopic asthma, as
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1394basophils, others inhibited allergen-induced basophil activation, at
least partly by inhibiting binding of IgE to specific allergen.
Conclusion: Naturallyoccurring IgGanti-IgEautoantibodiesmay
inhibit, aswell as induce, basophil activation. They act in amanner
distinct from therapeutic IgG anti-IgE antibodies such as
omalizumab. They may at least partly explain why atopic subjects
who make allergen-specific IgE never develop clinical symptoms,
andwhyomalizumab therapy is of variable clinical benefit in severe
atopic asthma. (J Allergy Clin Immunol 2014;134:1394-401.)
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basophil inhibition
IgE is thought to participate in host defense, but it also has a
central role in the pathogenesis of allergy and asthma.1 Basophils
and mast cells express the IgE high affinity receptor FcεRI and
mediate type I hypersensitivity reactions2 following cross-linking
of surface IgE-FcεRI complexes by multivalent antigens, including
allergens, causing activation/degranulation3 and clinical symptoms.
Previous studies in humans have identified the production of
autoantibodies of the IgGor IgMclass that bind specifically to IgEor
FcεRI. Some are able to activate basophils and mast cells
independently of antigens.4 Autologous serum skin tests,5 measure-
ment of histamine release frombloodbasophils,6 and,more recently,
basophil activation assays using flow cytometry7 have been used to
detect potential proinflammatory activities of these autoantibodies.
Most IgE-specific IgG autoantibodies are of the IgG1 or IgG4 iso-
type8 and appear to recognise 2 epitopes within the IgE Cε2 and
Cε4 domains.9 FcεRI-specific IgG autoantibodies of the IgG1 and
IgG3 isotypes have been described predominantly in patients with
chronic urticaria, while IgG2 and IgG4 isotypes have been described
in other autoimmune disorders.10 Autoantibodies against IgE or
FcεRI have been detected in various diseases, including atopic
dermatitis,11,12 asthma,13 and autoimmune disorders.10,14
Two general, striking features of these studies stand out. First,
not all of these autoantibodies show proinflammatory activ-
ity,15,16 at least as detected by the aforementioned assays, so their
activities do not reflect their concentrations,17 with 1 study hint-
ing at a possible regulatory role.8 Secondly, IgE-specific and
FcεRI-specific autoantibodies are also detectable in apparently
healthy individuals.18,19
Consequently, we set out to examine the possibility that IgG
anti-IgE autoantibodies may in some individuals exert an anti-
inflammatory, rather than a proinflammatory, effect. We elected to
focus on asthma as an archetypal disease involving IgE-mediated
mechanisms, inwhich exogenous IgG anti-IgE (omalizumab) has a
proven therapeutic role at least in some individuals, and on anti-IgE
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hypothesized that: (i) IgG anti-IgE autoantibodies are detectable
in the serum of all subjects but elevated in asthmatic subjects
regardless of atopic status as compared with controls; (ii) some of
these antibodies can activate IgE-sensitized basophils; (iii) some
of these antibodies do not activate IgE-sensitized basophils and
can, furthermore, inhibit allergen-induced activation.
To address these hypotheses, we developed and calibrated an
in vitro assay to detect and quantify IgG anti-IgE autoantibodies
in the serum of asthmatic subjects and controls. We then tested
the ability of these sera to activate or inhibit IgE-sensitized blood
basophils from a single atopic donor in the presence and absence
of allergen and finally utilized a rat basophilic cell line stably ex-
pressing human FcεRI bound to in-house manufactured mono-
clonal IgE directed against the Phl p 7 component of timothy
grass allergen20 to examine the ability of sera to inhibit the bind-
ing of these cells to specific allergen.METHODS
Participants
Atopic asthmatic (AA), non-atopic asthmatic (NAA), and non-atopic non-
asthmatic control (NAC) subjects were recruited from the departmental
asthma clinic at Guy’s Hospital, London and databases or through advertise-
ments. All participants gave written informed consent to participate in the
study, which was approved by a local research ethics committee. A diagnosis
of asthma was accepted based on relevant symptoms and 1 of the following
criteria: i) documented >_12% reversibility of FEV1 or PEFR in response to
inhaled bronchodilators (nebulized salbutamol 2.5 mg and ipratropium 500
mg); ii) documented >_8% variability of PEFR during a 24-hour period or
>_20% variability over a period of 1 to 2 weeks; or iii) a positive mannitol bron-
chial challenge test (Osmohale; Pharmaxis Pharmaceuticals Ltd, Burnham,
United Kingdom). Non-asthma was defined as absence of relevant symptoms,
with FEV1 in the normal range. Atopywas defined as a positive in vitro IgE test
to 1 or more of the following local aeroallergens: mixed grass, mixed tree,
mixed mould, house dust mite (HDM), and cat and dog dander. Non-atopy
was defined as negative in vitro IgE tests (Phadia ImmunoCAP; Thermo Fisher
Scientific, Uppsala, Sweden) (Grade 0 or <_0.35 kU/L) to the same aeroaller-
gens. The median and range % predicted FEV1 of the AA and NAA subjects
and the NAC at the time of the study were 97 (64-143), 73 (40-119) and 106
(94-128), respectively. All patient sera were screened for anti-nuclear
autoantibodies (ANA) using commercially available ANA-ELISA kits
(Abnova, Taipei City, Taiwan) according to the manufacturer’s instructions.ELISA
Maxisorp plates (Thermo Fisher Scientific) were coated either with 0.5 mg/
mL of recombinant IgE (Abcam, Cambridge, United Kingdom) to measure
IgG anti-IgE or with anti-human IgG (diluted 1:1000; AbD Serotec, Oxford,
United Kingdom) to measure total IgG, in 50 mM carbonate buffer pH 9.6 at
48C overnight. Non-specific binding was blocked with SuperBlock blocking
buffer (Thermo Fisher Scientific) or 3% milk powder (MP) in PBS-T at room
temperature (RT) for 2 hours, and the plates then washed 3 times with PBS-T.
Test sera were added at 1:5 to 1:20 dilutions in 1% MP-PBS-T and the plates
incubated at RT for 1 hour thenwashed 3 timeswith PBS-Tand incubatedwith
anti-human IgG-HRP (diluted 1:10000 in 1% MP-PBS-T; Sigma-Aldrich, St
Louis, Mo) for 1 hour at RT. The plates were washed again 3 times and the
color reaction developed using TMB solution (R&D Systems, Minneapolis,
Minn). The reaction was stopped by addition of 1.8 M H2SO4 and absorbance
read at 450 nm using a Multiskan EX plate reader (Thermo Fisher Scientific).
The assay was calibrated using a commercial IgG anti-IgE monoclonal
antibody (omalizumab; Novartis, Surrey, United Kingdom) or human IgG
(Sigma-Aldrich). All samples were measured at least in duplicate. To further
allow for any non-specific IgG binding to the plates and determine the
threshold of sensitivity of the anti-IgE ELISA (0.27 ng/mL), commercial hu-
man IgG (Sigma-Aldrich) was used at a relatively high concentration (2 mg/
mL) in place of sera as a negative control and the threshold defined as 3 stan-
dard deviations above the mean resulting absorbance.
The binding of IgG anti-IgE autoantibodies to FcεRI-bound IgE was
determined by pre-coating the ELISA platewith recombinant FcεRIa (0.5mg/
mL; R&D Systems) in carbonate buffer at 48C overnight. After washing 3
times with PBS-T and blocking with 3% MP in PBS-T for 2 hours at RT, the
plates were incubated overnight at 48C with recombinant IgE (0.5 mg/mL in
1%MP in PBS-T). Plates werewashed 3 times with PBS-T before the addition
of the test sera and the assay developed as described above. Each sample was
assayed at least in duplicate.Basophil activation test (BAT) by flow cytometry
PBMC from a single atopic non-asthmatic donor with total serum IgE >150
IU/mL and sensitized to HDM as determined by skin prick testing were
isolated using Ficoll-Paque PLUS (GE Healthcare, Amersham, United
Kingdom) and re-suspended in HBSS (Sigma-Aldrich) to a final concentration
of 2 x 107 cells/mL.
To test the activity of subject sera in the BATassay, 13 106 PBMC (50 mL
of suspension) were incubated with sera diluted 1:2 in BAT buffer to 50 mL
(HBSS with 2 mM CaCl2) for 30 minutes at 378C and the reaction stopped
by adding 2 mL of FACS buffer containing 2 mM EDTA on ice. The donor’s
own serum was used as a baseline control. As a positive control, instead of
sera, PBMC were activated using polyclonal anti-IgE (Dako, Glostrup,
Denmark) in the concentration range 6 ng/mL to 6 mg/mL in BAT buffer.
Flow cytometric analysis of basophil activation was adapted from a
previously published protocol.21 PBMC were stained with anti-CD203c-
phycoerythrin (Clone NP4D6; BioLegend, San Diego, Calif) and anti-
CD63-allophycocyanin (Clone MEM-259; BioLegend) using the
manufacturer’s recommended concentrations in FACS buffer (PBS containing
2% FBS) for 30 minutes on ice, washed in FACS buffer and analyzed using a
BD FACSCalibur (BD Biosciences, San Diego, Calif). Basophil activation
was defined as the percentage of CD203c1 basophils expressing the activation
marker CD63 compared with the baseline control.
Allergen-induced basophil activation
To determine the effect of subjects’ sera on allergen-induced basophil
activation, we pre-incubated 106 PBMCs in 50mL of BAT buffer from a single
atopic donor sensitized to HDMwith the sera (diluted 1:2 in BAT buffer to 50
mL), purified anti-IgE, or the donor’s own serum as a baseline control for 30
minutes at 378C. The cells were then washed and resuspended in 50 mL
BAT buffer prior to the addition of serial dilutions of the major HDM antigen
Der p 2 from 300 to 3 ng/mL for 30 minutes at 378C. The reactions were
stopped by adding 2 mL of FACS buffer containing 2 mM EDTA on ice,
and basophil activation was determined as described above.
AB
C
FIG 1. Concentrations of IgG anti-IgE autoantibodies in sera from non-
atopic controls, non-atopic asthmatic subjects, and atopic asthmatic sub-
jects (A). Dotted line shows 95% confidence limit of the range in controls.
Response of blood basophils to polyclonal anti-IgE in vitro (B). Basophil-
activating activity of sera (C). Dotted line shows detection threshold. Sam-
ples marked #were used for later experiments. Bars represent the mean/SD
of at least 3 independent experiments.
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sera
To deplete total IgG from sera, 500 mL samples were incubated with an
equal volume of protein G Sepharose (Sigma-Aldrich) at 48C overnight in a
mini Bio-Spin chromatography column (Bio-Rad, Hercules, Calif). The flow-
throughwas recovered and re-incubated with fresh protein G Sepharose at 48C
overnight. IgG was measured in the final recovered flow-through by ELISA.
To deplete IgE-binding proteins, IgE was cross-linked to cyanogen
bromide (CNBr)–activated Sepharose 4B (Sigma-Aldrich) according to the
manufacturer’s instructions. Briefly, 100mg of recombinant IgE anti-NP-BSA
(manufactured in-house) were mixed with 100 mL of 1 mM HCl-swollen
CNBr-activated Sepharose in coupling buffer (0.1 MNaHCO3 buffer contain-
ing 0.5MNaCl) at 48C overnight in a mini Bio-Spin chromatography column,
then washed with coupling buffer. Unconjugated sites were blocked with 0.2
M glycine buffer pH 8.0 for 2 hours at RT. After extensive washing with 5 cy-
cles of the coupling buffer and 0.1 M acetate buffer pH 4, the IgE-coupled Se-
pharosewas ready to be used. IgE-coupled Sepharose (50mL) was mixedwith
subjects’ sera (3 mL) at 48C overnight. The eluate containing non-IgE binding
antibodies was stored at 2208C for later analysis. Proteins bound to the IgE-
coupled Sepharose were then eluted with 100 mL of 0.2 M glycine pH 2.5 into
an equal volume of 100 mMTris buffer pH 8.0. The eluted solutions were dia-
lyzed in PBS at 48C overnight, then mixed with protein G Sepharose (1:1) at
48C overnight to capture IgG antibodies. The IgG anti-IgE antibodies were
eluted off the protein G Sepharose with glycine, dialyzed with PBS as above,
then quantified by ELISA and run on 10% SDS-PAGE under non-reducing
conditions compared with recombinant IgE and IgG (Sigma-Aldrich). Nocontaminating IgE was found in purified antibodies, as determined by total
IgE ELISA (individual data not shown; see Fig E1, C, in this article’s Online
Repository at www.jacionline.org).Effects of sera on allergen binding to IgE-bound
basophils
To determine the effects of our test sera on allergen binding to IgE on the
surface of basophils, we used pure, recombinant Phl p 7–specific IgE subcl-
oned from an existing IgG4 clone isolated in-house
20 by replacement of the
Cg4 constant region with that of IgE (Cε; Dodev et al; manuscript in press).
Cells of the RBL-SX38 rat basophilic cell line, which stably express human
FcεRI,22 were cultured in RPMI-1640 medium (Sigma-Aldrich) containing
10% FBS (Sigma-Aldrich), 1% Penicillin-Streptomycin-Glutamine (Life
Technologies, Carlsbad, Calif) and 1 mg/mL Genticin (Life Technologies).
RBL-SX38 cells were harvested and resuspended in BAT buffer at 2 3 107
cells/mL, then incubated with Phl p 7–specific IgE at a concentration of 0.5
mg/mL in 50 mL BAT buffer for 30 minutes at 378C. Aliquots of 106 cells
werewashedwithHBSS and incubatedwith 50mL aliquots of the sera (diluted
1:2 in BAT buffer) for 30 minutes at 378C. After further washing with HBSS,
the cells were resuspended and incubated with 50 mL of 1 mg/mL of in-house
produced, freshly biotinylated Phl p 7 diluted in BAT buffer for 30 minutes at
378C. Surface-bound IgE was detected using anti-IgE-FITC (Vector Labora-
tories, Burlingame, Calif) and Phl p 7 binding to this IgE using
streptavidin-APC (BioLegend), with analysis by flow cytometry.Statistical analysis
Statistical analysis was performed using 2-way ANOVA with Bonferroni
correction or as otherwise stated. A P value of < .05 was considered significant
(*P < .05, **P < .01, ***P < .001).
RESULTS
Identification of naturally occurring IgG class
autoantibodies against free and FcεRI-bound IgE
Serum samples were screened for IgG-class antibodies specific
for IgE using an in-house, custom ELISA as described in the
Methods section. IgG anti-IgE autoantibodies were detected
above the threshold of sensitivity of the assay after allowing for
non-specific binding in all subjects in all 3 groups, with concentra-
tions ranging from 22 to 223 ng/mL, 11 to 1761 ng/mL, and 39 to
1070 ng/mL in the NAC, NAA, and AA, respectively (Fig 1, A).
Omalizumab was used as a standard to calibrate the ELISA (see
Fig E1, A). A ‘‘normal’’ range for these measurements has yet to be
defined, but some serum samples from the asthmatic subjects
clearly showed concentrations of IgG anti-IgE in excess of the
95% confidence limit of the measurements in the normal controls
(Fig 1,A).Nevertheless,manydid not, and overall, therewas no sig-
nificant variation in the concentrations of these antibodies between
the 3 groups. Therewereno systematic differences inbindingof any
of the IgE-specific autoantibodies to IgE alone and FcεRI-bound
IgE, although in2of the samples fromthenon-atopic asthmatic sub-
jects (NAA9 and NAA17), binding of the autoantibodies to FcεRI-
bound IgE was below the lower limit of detection of the assay and
therefore technically unquantifiable (see Fig E1, B). Purified IgG
anti-IgE autoantibody from a single patient’s serum was used as a
standard to calibrate the ELISA for measuring FcεRI-bound IgE,
because omalizumab does not bind to FcεRI-bound IgE. Gel elec-
trophoresis confirmed that this antibody, as well as antibodies from
the remainder of the study subjects, was pure and, in particular, free
of contaminating IgE (see Fig E1, C and D).
Concentrations of IgG anti-IgE antibodies were compared with
those of total IgE and anti-nuclear autoantibodies in all of the
AB
FIG 2. Concentration/response curve of blood basophils from a Der p
2–sensitized atopic donor to Der p 2 allergen in vitro (A). Response of the
same basophils to Der p 2 30 ng/mL pre-incubated with all sera from
Fig 1 normalized to baseline (pre-incubation of the cells with the donor’s
own serum) (B). Bars represent the mean/SD of at least 3 independent
experiments.
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at www.jacionline.org). No correlation was observed in either
case.Basophil activation by sera containing IgG anti-IgE
autoantibodies
Sera containing IgG anti-IgE specific autoantibodies were
tested for their ability to activate blood basophils from a single
atopic donor using a standard flow cytometric basophil activa-
tion assay. As a positive control, incubation of the donor
basophils with polyclonal, exogenous IgG anti-IgE covering the
concentration range observed in the sera of the study subjects
induced concentration-dependent activation as measured by
increased CD63 expression (from 3.15% to 85.6%; Fig 1, B;
and see Fig E3 in this article’s Online Repository at www.
jacionline.org). To examine autoantibody activity, these same
donor basophils were incubated with subjects’ serum samples.
Basophil activation was defined as >2.67% CD631 cells, or 3
standard deviations above the mean percentage of basophils ex-
pressing CD63 following incubation with the donor’s own
serum under identical conditions as a baseline. According to
these criteria, sera from 2 non-atopic asthmatic subjects
(NAA7, NAA18) and 3 atopic asthmatic subjects (AA5, AA8,
AA14) were able to activate basophils directly, whereas the
others were not (Fig 1, C). This activity did not equate with
elevated IgG anti-IgE autoantibody concentrations: not all
basophil-activating sera contained high concentrations of IgG
anti-IgE (Fig 1: AA8), while not all high IgG anti-IgE sera acti-
vated basophils (Fig 1: NAA2, NAA16, AA12).Modification of allergen-induced basophil
activation by IgG anti-IgE autoantibodies
Considering the above data, we examined the ability of sera
from all of the donors to modify allergen-induced activation ofblood basophils from the same single atopic donor who was
sensitized to the major dust mite allergen Der p 2. Following pre-
incubation of the donor’s basophils with the donor’s own serum,
Der p 2 induced concentration-dependent basophil activation (Fig
2, A). None of the 5 basophil-activating sera, when pre-incubated
with the same donor basophils under identical conditions, signif-
icantly reduced the degree of basophil activation induced by a
concentration of Der p 2 optimal for this donor (Fig 2, B) and a
range of higher and lower concentrations (Fig E4, A, in this arti-
cle’s Online Repository at www.jacionline.org: paucity of sample
precluded further analysis of serum from subject AA14). In
contrast, sera from 2 subjects (NAA16 and AA12), which did
not directly increase basophil activation, significantly inhibited
allergen-induced activation, while serum from a third subject
(NAA2) exhibited an inhibitory effect of borderline significance
(Fig 2, B, and Fig E4, B, in this article’s Online Repository at
www.jacionline.org).Depletion of total IgG and IgE-binding proteins
from inhibitory sera abolished inhibition of
allergen-induced basophil activation
To further characterize the observed inhibitory activity of the
sera from subjects NAA16 and AA12 on allergen-induced
basophil activation, we depleted either IgG (Fig 3, A) or IgE-
binding proteins (Fig 3, B). Both maneuvers essentially abolished
the ability of the sera to inhibit allergen-induced basophil activa-
tion, whereas purified IgE-binding proteins retained this activity
in full (Fig 3, C and D). As a negative control to demonstrate
that depletion of IgG or isolation of IgE-binding proteins did
not generate basophil modifying activity per se, we showed that
similar extracts from the non-inhibitory serum NAA7 showed
no significant effects on allergen-induced basophil activation
(Fig E4, C).Allergen binding to IgE is inhibited by IgG anti-IgE
antibody containing sera
To begin to address the mechanisms of inhibition of allergen-
induced basophil activation by the inhibitory sera NAA16 and
AA12, we used the rat basophilic cell line RBL-SX38, which
expresses surface human FcεRI, and recombinant IgE specific for
the timothy grass allergen Phl p 7.20 Flow cytometric analysis
confirmed binding of recombinant IgE anti-Phl p 7 to the FcεRI
expressed on the surface of the RBL-SX38 cells (Fig 4, A). Simi-
larly, subsequent addition of fluorochrome-tagged, recombinant
Phl p 7 to the IgE-coated cells resulted in its binding to this spe-
cific antibody (Fig 4, B). Pre-incubation of IgE-bound RBL-
SX38 cells with 4 of the sera that activated basophils directly
ex vivo but did not modify allergen-induced basophil activation
ex vivo (NAA7, NAA18, AA5, andAA8; Fig 2,B: wewere unable
to re-test serum AA14 owing to paucity of sample), or 1 serum
sample from a donor in each group selected to contain anti-IgE
at the threshold of the mean concentration observed in the con-
trols with no basophil activating activity (NAC5, NAA11, AA9)
prior to the addition of Phl p 7 did not significantly alter surface
IgE or Phl p 7 binding (Fig 4, C and D). In contrast, 2 of the sera
that inhibited allergen-induced basophil activation ex vivo
(NAA16 and AA12, Fig 2, C) significantly reduced binding of re-
combinant allergen but not allergen-specific IgE to the RBL-
SX38 cells (Fig 4, C and D).
A B
DC
FIG 3. Total IgG concentrations in 2 test sera ex vivo and following protein G depletion (A). IgE-binding pro-
teins ex vivo and following depletion and isolation of IgE binding proteins (B). Effects of sera ex vivo and
following IgG depletion (C) and removal and purification of IgE binding proteins (D) on Der p 2 (30 ng/
mL)–induced basophil activation normalized to baseline (using the donor’s own serum). Bars represent
the mean/SD of 3 independent experiments. *P < .05 and ***P < .001.
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We describe a novel and quantitative technique for the
measurement of serum IgG anti-IgE autoantibodies. Hitherto
these have been identified indirectly using histamine release
assays,23 or expressed as arbitrary optical density readings in
uncalibrated ELISA.8,24 Using recombinant IgE as the capture an-
tigen and a pan-anti-human IgG polyclonal antibody for detec-
tion, we have been able to calibrate the ELISA using known
concentrations of omalizumab, a monoclonal IgG anti-IgE
antibody.
Using this assay, we show that there is a subset of asthmatic
patients who, regardless of conventional atopic status, have
circulating IgG anti-IgE autoantibodies in excess of the range
observed in a group of non-asthmatic control subjects, although
this is not a consistent finding in the asthmatic subjects and does
not permit a clear statistical distinction between the groups.
Nevertheless, these observations are of great interest to us from
the point of view of a possible role for IgE-mediated mechanisms
in asthma, since we have previously reported data suggesting that
IgE is expressed to excess in the bronchial mucosa of asthmatic
patients regardless of conventional atopic status,25,26 and the
additional presence of systemic IgG anti-IgE autoantibodies
capable of directly activating cells bearing sufficient surface-
bound IgE27 could represent a mechanism for local, allergen-
independent disease exacerbation. Equally significantly, however,
our data also show that some IgG anti-IgE autoantibodies actually
inhibit allergen-induced activation of basophils expressing sur-
face allergen-specific IgE, at least partly by inhibiting the binding
of this IgE to allergen. This may explain why, in this and previousstudies, measured concentrations of these antibodies correlate
poorly with their clinical effects,28,29 and also why they do not
necessarily cause disease.28 More fundamentally, though, they
may at least partly explain phenomena such as why some atopic
subjects who manufacture allergen-specific IgE do not develop
allergic disease, and why in some patients with asthma, who
may manufacture IgE inhibitory IgG endogenously, exogenously
administered IgG anti-IgE therapy such as with omalizumab prof-
fers little additional clinical benefit. These questions are readily
addressable in future studies.
It is not clear what regulates the production of IgG anti-IgE
autoantibody in individual subjects. We observed no correlation
between the production of IgG anti-IgE antibodies and the
production of other potentially pathogenic IgG autoantibodies
such as anti-nuclear autoantibodies (see Fig E2, B). Similarly, and
in contrast to certain earlier studies,13,30 we observed no correla-
tion in individual subjects between serum total IgE and IgG anti-
IgE concentrations (see Fig E2, A). This may reflect low subject
numbers, interference by IgE-specific autoantibodies with the
determination of total IgE using different techniques,31 or a true
lack of any relationship.
Although we studied the properties of IgG anti-IgE autoanti-
bodies from considerable numbers of non-atopic controls and
non-atopic and atopic asthmatic subjects in this study, it is clearly
arguable that, as in all similar studies, wemay not have defined all
of the properties of these antibodies or their relative incidence in
the entire source populations in an unbiased manner. Having said
this, we observed that in no case was their binding inhibited by
prior binding of the IgE to its high-affinity receptor FcεRI,
FIG 4. Binding of recombinant Phl p 7-specific IgE to FcεRI on RBL-SX38 cells (A). Phl p 7 binding following
further incubation with specific allergen (representative of 3 independent experiments) (B). Changes in
surface-bound IgE (C) and surface-bound Phl p 7 (D) on RBL-SX38 cells pre-incubated with recombinant,
anti-Phl p 7 IgE test sera then Phl p 7 compared with no serum control. Bars represent the mean/SD of 3 in-
dependent experiments. **P < .01 and ***P < .001.
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attached to its high-affinity receptor in vivo. This is in contrast to
omalizumab, which binds only free IgE. Our findings are
congruent with previous studies9 suggesting that the majority of
IgG anti-IgE autoantibodies recognize the Cε2 or Cε4 domains
of IgE, and not the Cε3 domain to which omalizumab is thought
to bind32 and which is inaccessible when the IgE is bound to its
high- or low-affinity receptor. The fact that complete removal
either of total IgG or of total IgE binding proteins abolished
basophil-modifying activity, whereas the purified IgE binding
proteins retained it, is consistent with the hypothesis that it is
entirely attributable to IgG anti-IgE. Furthermore, that fact that
such activity did not ‘‘appear’’ in fractionated serum from
subjects not showing it ex vivo (Fig E4,C) excludes the possibility
that it is an artefact of the separation procedure. Nevertheless, we
cannot completely exclude the possibility that some basophil-
modifying activitymay have reflected the alternative or additional
presence of IgG anti-FcεRI autoantibodies.27,33-35 We have been
able to detect such antibodies by further modification of our
in vitro assays, and further exploration of the properties of these
antibodies is the subject of an ongoing further study. The unprec-
edented potential protective effect of some of these antibodies,however, is of great interest regardless of their precise
specificities.
We undertook some preliminary investigations as to possible
mechanisms by which inhibitory IgG anti-IgE autoantibodies
could reduce allergen-induced basophil activation in our patients.
Those we studied did not appear to dissociate IgE from its
receptor, a property suggested in previous reports,36-38 but some
did appear to be able to prevent allergen binding to surface-
bound specific-IgE, presumably without cross-linking it. This
could reflect the inability of IgG anti-IgE in the IgG-IgE-FcεRI
complex to interact with another IgE on the cell surface for a va-
riety of reasons.39 Further possible mechanisms of basophil inhi-
bition by these antibodies not explored in the present study are
also conceivable, such as cross-linking of FcgRIIb with
FcεRI.40-42 It is worth noting again that the activities of these
IgG anti-IgE autoantibodies are quite different from those of oma-
lizumab, which appears to exert its clinical effects simply by pre-
venting binding of IgE to its high- and low-affinity receptors, and
do not appear to reduce the intrinsic sensitivity of basophils to
activation: on the contrary, recent experiments43,44 by MacGla-
shan and other colleagues suggest that sequestration of IgE
during omalizumab therapy renders basophils hypersensitive to
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cules, at least partly by resetting of FcεRI coupled intracellular
signalling.
It is finally apposite to note that production of IgG anti-IgE
autoantibodies has been documented in murine ‘‘models’’ of
allergen sensitization and tolerance45 and in the course of specific
allergen immunotherapy in humans,16,46 which induces a
vigorous IgG4 response that could, at least in theory, include
IgG anti-IgE autoantibodies. Indeed, 1 of these studies on wasp
venom immunotherapy16 linked the elevated production of
basophil-activating IgG anti-IgE autoantibodies with treatment
failure. The experiments in mouse models and immunotherapy
in humans have led to speculations about activating but not inhib-
itory antibodies, which may also be prevalent.
In summary, inhibitory IgG anti-IgE autoantibodies may
contribute to a natural regulatory mechanism that could conceiv-
ably influence the severity and presence or absence of diseases
with IgE-mediated mechanisms, including asthma and allergic
rhinitis, and the outcomes of therapeutic processes such as
allergen immunotherapy and therapy with exogenous IgG anti-
IgE. This demands further, potentially extremely exciting,
research.
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FIG E1. Representative standard concentration curve for the IgG anti-IgE ELISA using omalizumab (A).
Comparison of the capacity of IgE-specific IgG autoantibodies to bind to ‘‘free’’ IgE (dark bars) and FcεRI-
bound IgE (white bars) # analyte below detection limit of assay. Bars showmean/SD of 3 experiments using
duplicate samples (B). SDS-PAGE showing the purified IgG anti-IgE from serum compared with recombi-
nant IgE and IgG (C). Representative standard concentration curve for the IgG anti-FcεRI-bound ELISA using
anti-IgE purified from human sera (D).
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FIG E2. Comparison of serum total IgE and IgG anti-IgE autoantibody
concentrations in all study subjects (A). Spearman r5 0.08578; P > .5. Com-
parison of serum concentrations of IgG anti-IgE antibodies with ANA in all
study subjects (B). Dotted line shows the threshold for a positive ANA
result. Spearman r 5 20.02621; P > .5.
J ALLERGY CLIN IMMUNOL
VOLUME 134, NUMBER 6
CHAN ET AL 1401.e2
FIG E3. Gating strategy to determine basophil activation by flow cytometry, comparing unstimulated and
anti-IgE–stimulated PBMC.
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FIG E4. Response of blood basophils stimulated with Der p 2 (3 to 300 ng/mL), pre-incubated with 4 sera
containing IgG anti-IgE autoantibodies and basophil-activating activity (A) and 3 sera containing IgG anti-
IgE autoantibodies without basophil-activating activity normalized to baseline (pre-incubation of the cells
with the donor’s own serum) (B). Effects of the non-inhibitory serum NAA7 following the removal and pu-
rification of IgE binding proteins on Der p 2 (30 ng/mL)–induced basophil activation (C). Bars represent the
mean/SD of 3 independent experiments. *P < .05, **P < .01, and ***P < .001.
J ALLERGY CLIN IMMUNOL
VOLUME 134, NUMBER 6
CHAN ET AL 1401.e4
